MOTS-c Protocol: Experimental Design, Not Clinical

A MOTS-c protocol, as the term is used online, is typically four lines long: a route, a quantity, an interval and a duration. A protocol in the sense used by the people who run studies is a controlled document running to dozens of sections, and the difference between the two is not length for its own sake.

Each section of the long version exists because something went wrong without it. Reading the two documents side by side is the fastest way to see what a four line version cannot tell you, and it is more informative than arguing about the four numbers.

One word covering two different documents

The research sense of the word denotes the pre specified plan for a study: who may enrol, how they are allocated, what is administered, what is measured, when, by whom, how the data will be analysed, and what happens if someone is harmed. It is written before the first participant is enrolled, it is registered, and amendments to it are recorded.

The consumer sense denotes an administration schedule. It answers only the intervention question, and it answers it without reference to who is administering, what is being measured, or how anyone would know whether it worked.

Both are called protocols. Only one is a design.

What the long version contains

The elements are not decorative. Eligibility criteria define the population a result applies to, which is why a finding in adults with prediabetes cannot be quoted as a finding in healthy young athletes. Randomisation with concealed allocation prevents the person enrolling participants from steering healthier ones into the treatment arm. Blinding prevents both the participant’s expectation and the assessor’s expectation from becoming the effect.

Pre specified primary outcomes prevent the study from being rescued afterwards by whichever of twenty measurements happened to move. A sample size justification states in advance what effect the study can detect, which is what stops a null result from being read as evidence of no effect when the study was simply too small to see one. A statistical analysis plan fixes the analysis before the data exist. Safety reporting defines what counts as an adverse event and where it goes. Ethics approval places responsibility for harm somewhere other than on the participant.

Two further sections rarely get mentioned outside the field and both change how a result should be read. Stopping rules and independent monitoring determine whether a study can be halted early for harm or for benefit, and early stopping tends to exaggerate an effect estimate, so knowing the rule matters when the number is interpreted. And the analysis population is defined in advance: an intention to treat analysis counts everyone as randomised, while a per protocol analysis counts only those who completed as specified. The second reliably looks better, because the people who drop out are not a random sample of the enrolled. Which population a headline figure came from is often the difference between a modest result and an impressive one.

Strip those out and what remains is the intervention line: substance, route, quantity, frequency, duration. That line is the only part that survives into the consumer version.

What circulates instead, and where it came from

Trace a circulating MOTS-c protocol and it generally resolves into an animal study’s administration parameters with the species removed, a vendor’s suggestion, or a forum consensus that has drifted through repetition.

None of those origins involves a measurement in a person. The formatting does a lot of work here: a table with units and intervals reads as though a study stands behind it, and the reader has no way to see that nothing does unless someone traces it.

There are also two citation traps specific to this compound, and a circulating protocol may rest on either. A keyword search of a trial registry matches text anywhere in a record, so a search returns studies involving anaesthesia, vestibular implants and exercise programmes in unrelated patient groups. Those are false matches. The second trap is heavier: the one record that does name this compound is not a study of it, which is taken apart below. A protocol citing a count from either source is citing nothing.

MOTS-c protocol elements: registered study against circulating post

The organism column belongs here as a footnote rather than a column: every row in the middle applies to human participants, and the supporting evidence base for this compound consists of mice, rats and cultured cells, in which none of these human protections are the relevant question.

Why the registry entry is not a substitute, and not a study

A registration is a commitment to a plan. Its value is that it makes selective reporting visible later: if the published paper reports a different primary outcome from the registered one, that is detectable. It is not a finding, it is not an endorsement, and it is not a document to follow. Registries accept records from sponsors rather than auditing them, so an entry says that someone filed something.

That last point is usually a caveat and here it is the whole story. NCT07505745 reads as a Phase 2 study of this compound in adults with prediabetes and overweight or obesity, planned enrolment 120, recruiting. Its lead sponsor also appears on seven other records first posted between February and April 2026, all recruiting, all naming a single site, covering BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide and TB-500. One of the seven says in its own brief summary that it is a fictional example of a registry style record, and the sponsor has no drug application in FDA Drugs@FDA. There is no genuine registered human trial of this compound.

For an article about what a protocol is, that is the sharpest available illustration. The forty section document exists to make a claim checkable. A registry entry carries almost none of that weight, which is why it cannot be followed as a protocol, and as this record shows it carries no guarantee that the study behind it exists. Two fields settle that, the lead sponsor and the brief summary.

What a defensible individual experiment would look like

If someone were determined to generate information rather than an anecdote, the elements are borrowable even if the study is not.

Pre specify the outcome and the assay before starting, in writing. Use one laboratory and one procedure for every measurement. Hold the obvious confounders constant, particularly diet and training, and record deviations. Define in advance how long the observation runs and what result would count as nothing happening. Publish the record whichever way it comes out.

That produces a single case with a control group of none, which is still a weak design. It is, however, honestly weak rather than misleadingly strong, and it removes the three failure modes that make most circulating accounts uninterpretable: outcome selection after the fact, measurement drift, and silent abandonment when nothing happens. The remaining limitation is structural. One person cannot generate the comparison a control arm provides, which is the reason trials exist and the reason a four line document will never do the work of a forty section one.